Oregon Pacific Wealth Management LLC bought a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,252 shares of the company’s stock, valued at approximately $281,000.
A number of other institutional investors also recently modified their holdings of the company. Concord Wealth Partners purchased a new stake in Cencora in the third quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares during the period. Ashton Thomas Securities LLC purchased a new stake in Cencora in the third quarter worth about $41,000. Modus Advisors LLC purchased a new stake in Cencora in the fourth quarter worth about $54,000. Finally, Carolina Wealth Advisors LLC lifted its holdings in Cencora by 366.7% in the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after buying an additional 209 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Cencora
In related news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock worth $17,790,912 in the last three months. Insiders own 10.80% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Report on Cencora
Cencora Stock Performance
Shares of NYSE COR opened at $254.11 on Monday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company has a market cap of $49.11 billion, a P/E ratio of 33.84, a P/E/G ratio of 1.61 and a beta of 0.49. The firm’s fifty day moving average is $238.74 and its two-hundred day moving average is $235.97. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $261.25.
Cencora Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s payout ratio is 29.29%.
Cencora Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- How to Use Stock Screeners to Find Stocks
- Reshoring Riches: Investing in Made in America 2.0
- How to Buy Cheap Stocks Step by Step
- 3 REITs to Watch as Interest Rates Keep Falling
- What is the FTSE 100 index?
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.